RxDoctor Payments Data

Batool Mir, MD

Family Medicine · Lansing, MINPI 1366482937

Payments from drug & device makers

$14,153in general payments, 2019–2025

Across 847 payments — averaging $16.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amgen$2K
  • Novo Nordisk$2K
  • AbbVie$1K
  • Lilly USA, LLC$839
  • Pfizer$836
  • plus $6K from 41 others

What the payments were for

  • Food & beverage$14,093100%
  • Education$600%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,153 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$37,857
Medicare patients
106
Services billed
550

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol95$119,997
Trelegy ElliptaFluticasone/Umeclidin/Vilanter99$118,557
JardianceEmpagliflozin61$89,331
TrulicityDulaglutide40$50,229
OzempicSemaglutide35$45,118
EliquisApixaban27$41,864
RybelsusSemaglutide17$36,649
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog31$31,234
ProliaDenosumab17$28,732
XareltoRivaroxaban19$28,255
MyrbetriqMirabegron25$25,070
JanuviaSitagliptin Phosphate23$23,804
GemtesaVibegron16$20,936
ViberziEluxadoline12$18,738
Soliqua 100-33Insulin Glargine/Lixisenatide20$18,035

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$767$127,225110 claims
AstraZenecaFarxiga, Symbicort$2,331$123,973110 claims
Boehringer IngelheimJardiance, Tradjenta$410$105,55172 claims
Novo NordiskOzempic, Rybelsus$1,579$81,76652 claims
Lilly USA, LLCTrulicity$839$50,22940 claims
PfizerEliquis$836$41,86427 claims
MerckJanuvia, Janumet$369$38,97736 claims
AbbVieViberzi, Linzess$1,270$32,77424 claims
AmgenProlia$1,751$28,73217 claims
Johnson & JohnsonXarelto$100$28,25519 claims
Astellas Pharma US IncMyrbetriq$51$25,07025 claims
Sumitomo Pharma America, Inc.Gemtesa$138$20,93616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →